The Effect of Peptide Immunotherapy on Frequency, Memory Phenotype, Chemokine Receptor Expression and Markers of Regulatory T Cell Function Among Allergen-Specific T Cells. A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy (DAIT U19-MMU-02)

Trial Profile

The Effect of Peptide Immunotherapy on Frequency, Memory Phenotype, Chemokine Receptor Expression and Markers of Regulatory T Cell Function Among Allergen-Specific T Cells. A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy (DAIT U19-MMU-02)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2016

At a glance

  • Drugs Cat SPIRE (Primary)
  • Indications Allergic asthma; Allergic rhinoconjunctivitis; Hypersensitivity
  • Focus Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 13 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top